Published August 11, 2026 | Version v1

A Review on Bioanalytical Method Development and Validation of Pioglitazone by RP-HPLC

Description

Bioanalytical method development is a process of designing and optimizing an analytical method for quantitative estimation of drug of interest in biological matrices like plasma, serum, urine, saliva etc. Pioglitazone is a thiazolidinedione antidiabetic drug, a selective agonist of Peroxisome Proliferator Activated Receptor gamma (PPAR-γ) used in the treatment of Type 2 diabetes mellitus. The determination of its concentration in biological samples is essential for pharmacokinetic studies, therapeutic drug monitoring, drug interaction assessment, bioequivalence evaluation and regulatory acceptance. This is because of its extensive therapeutic use and the growing interest in its pharmacokinetics and in achieving consistent therapeutic exposure in patients in the clinical setting. This review updates the recent advances and strategies in bioanalytical techniques for the analysis of pioglitazone with special emphasis on reverse phase high-performance liquid chromatography (RP-HPLC) as the method of choice. This review also highlights the rationale behind IS selection, including the utilization of stable isotope-labelled (SIL) compounds, structurally related drugs, which enhance the reliability and robustness of the method. Furthermore, this review addresses the significance of optimizing sample preparation techniques, such as protein precipitation (PP), liquid–liquid extraction (LLE), and solid-phase extraction (SPE), to improve analyte recovery and validate methods for reliability. This review also emphasizes emerging trends, including the integration of automation and artificial intelligence in method development, and identifies current challenges, such as matrix complexity and analyte stability. By addressing existing challenges and proposing best practices, this review contributes to the advancement of bioanalytical research in diabetes management, aiding the optimization of pharmacokinetic studies and therapeutic monitoring of Pioglitazone. Future research should focus on impurity profiling, stress degradation studies, and quantification of pioglitazone in human plasma. This review offers a comparative overview for researchers and practitioners aiming to improve bio analytical methodologies in the field of anti-diabetic drug analysis.

Files

38-Sandra Chandran.pdf

Files (4.3 MB)

Name Size
md5:bdd73d5ab08a96119d8b1aa9dd405d03
4.3 MB Preview Download